Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
View Patent ↗The invention relates to triazole compounds of the general formula I wherein R 1 is hydrogen or methyl, and R 2 is C 3 -C 4 alkyl or C 1 -C 2 fluoroalkyl, as well as the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
1. A triazole compound of the formula I
wherein
R 1 is selected from the group consisting of hydrogen and methyl; and
R 2 is selected from the group consisting of C 3 -C 4 alkyl and C 1 -C 2 fluoroalkyl;
or the physiologically tolerated acid addition salts thereof.
2. A compound as claimed in claim 1 , wherein R 1 is methyl.
3. A compound as claimed in claim 1 , wherein R 1 is hydrogen.
4. A compound as claimed in claim 1 , wherein R 2 is tert-butyl.
5. A compound as claimed in claim 4 , wherein R 1 is methyl.
6. A compound as claimed in claim 4 , wherein R 1 is hydrogen.
7. A compound as claimed in claim 1 , wherein R 2 is trifluoromethyl.
8. A compound as claimed in claim 7 , wherein R 1 is methyl.
9. A compound as claimed in claim 7 , wherein R 1 is hydrogen.
10. A compound as claimed in claim 1 , wherein R 2 is n-propyl.
11. A compound as claimed in claim 10 , wherein R 1 is methyl.
12. A compound as claimed in claim 10 , wherein R 1 is hydrogen.
13. A compound as claimed in claim 1 , selected from the group consisting of
2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-tert-butyl-pyrimidine,
2-tert-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine,
2-tert-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-difluoromethyl-pyrimidine and
2-tert-Butyl-4-{4-[3-(4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-tert-butyl-pyrimidine,
2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-trifluoromethyl-pyrimidine,
and the physiologically tolerated acid addition salts of these compounds.
14. A pharmaceutical composition comprising at least one compound as claimed in claim 1 together with at least one physiologically acceptable carrier or auxiliary substance.
15. A method for treating schizophrenics, said method comprising administering an effective amount of at least one compound as claimed in claim 1 to a subject in need thereof.